Do you want to read an article? Please log in or register.
SBRT Plus Nivolumab in Advanced NSCLC: A Phase II Multicenter Study With Exploratory Bone Metastases Subgroup Analysis
Lung Cancer
Related content
Lung Cancer
ENTRÉE Lung Platform Trial Sub-study 1: Phase II Randomized Efficacy and Safety Analysis of Feladilimab Plus Docetaxel Versus Docetaxel Monotherapy in Advanced/Recurrent NSCLC
Clin Lung Cancer
Garassino MC, Cousin S, Besse B, Sacher A, Orlov S, Schenker M, Felip E, Gladkov O, Messina CH, Majumdar A, Wu ZJ, Karpinich NO, Hirschfeld S, Ballas M, Reck M
doi: 10.1016/j.cllc.2026.04.003
Lung Cancer
Nivolumab plus chemoradiotherapy followed by nivolumab with or without ipilimumab for untreated locally advanced stage III NSCLC: a randomized phase 3 trial
Nat Cancer
Peters S, Tan DSW, Gerber DE, Urbanic J, Ramalingam S, Yu J, Xing L, Rittmeyer A, Ciuleanu TE, de Menezes J, Kim HR, Rojas C, Syrigos K, Hayashi H, Haridass A, Cortinovis D, Bruno D, Kimmich M, Calles A, Nathani R, Pudussery G, Yang L, De Ruysscher D
doi: 10.1038/s43018-026-01161-y
Further Publications
Population pharmacokinetics and exposure-response analysis of durvalumab in patients with resectable stage II to IIIB (N2) NSCLC in the phase III AEGEAN study
Br J Clin Pharmacol
Zhao X, Ding J, Zhao J, Zhang L, Abegesah A, Zhang YQ, O'Brien C, Doherty GJ, Chen AC, Lim K, Ren S, Ma P, Zhou D
doi: 10.1002/bcp.70287
RECOMMENDED
Lung Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr. med. Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
Lung Cancer
Double-dose firmonertinib as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer harboring EGFR L858R mutation: a prospective, multicenter, phase II study (FIRM)
Nat Commun
Shen B, Wang C, Zhang L, Zhu Y, Zhang X, Wang X, Guo Z, Wang L, Wang X, Zhu L, Zhou Y, Liao D, Shi M
doi: 10.1038/s41467-026-68554-6
Lung Cancer
Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis
Nat Commun
Zhang B, Zhong R, Shi C, Chu T, Zhang W, Wang H, Gan X, Zhang Z, Zhu C, Li X, Su W, Li J, Zhang Y, Han B, Zhong H
doi: 10.1038/s41467-026-73562-7
Lung Cancer
Savolitinib Plus Osimertinib in Epidermal Growth Factor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial
Clin Lung Cancer
Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW
doi: 10.1016/j.cllc.2025.10.018
Lung Cancer
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 Trial
J Thorac Oncol
Baramidze A, Makharadze T, Gogishvili M, Melkadze T, Giorgadze D, Penkov K, Laktionov K, Nemsadze G, Nechaeva M, Rozhkova I, Kalinka E, Li Y, McIntyre DAG, Jia X, Perez J, Kaul M, Lowy I, Pouliot JF, Chua S, Kim E, Seebach F, Magnan H
doi: 10.1016/j.jtho.2026.103980
Lung Cancer
Cadonilimab plus chemotherapy as first-line treatment in PD-L1-negative advanced non-small cell lung cancer: a phase II clinical trial
Nat Commun
Wang L, Rao C, Wang Q, Huang K, Liu L, Zhao J, Wu Y, Chen J, Qian J, Lu H, Pan S, Nie L, Tang H, Dong H, Jia SD, Zang Y, Chu T, Su C
doi: 10.1038/s41467-026-74241-3